Immune Response + 20% - 500 Beiträge pro Seite

[VonHinten]

Hi Schaut mal rein.

[tradefunny]

Killer T Cells Against the AIDS Virus Appear to be Activated By Combination Treatment With REMUNE(TM) (Investigational HIV-1 Immunogen) and Antiviral Drugs
Data Reported at the 13th International AIDS Conference
CARLSBAD, Calif., July 13 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that preliminary interim clinical results from an ongoing Phase II trial in Spain indicate that functionally active cytotoxic T lymphocytes (CTL) or ``killer`` T cells appear to be stimulated in HIV-positive individuals treated with the Company`s investigational product REMUNE(TM) (HIV-1 Immunogen) in combination with antiviral drug therapy (ART). CTLs are white blood cells of the immune system that are capable of killing cells infected with HIV.

Professor Eduardo Fernandez-Cruz, M.D., Ph.D., Head of the Division of Clinical Immunology at University General Hospital ``Gregorio Maranon`` in Madrid and Principal Investigator of the Phase II trial of REMUNE in Spain presented the data in an oral presentation at the 13th International AIDS Conference in Durban, South Africa.

Dr. Fernandez-Cruz commented, ``We observed an increase of a specific subset of T cells displaying cell-surface proteins that are characteristic of effector CTLs in REMUNE-treated individuals. Importantly, this investigation has also shown that those effector CTLs are functionally active, that is to say, they have the capability to kill cells expressing HIV antigens.`` Dr. Fernandez-Cruz indicated that the CTL analysis includes a total of 23 patients and confirms earlier results indicating that REMUNE may enhance the population of memory CTLs (cells that can become effector CTLs upon re-exposure to a particular pathogen) in patients concurrently on antiviral drug therapy.

``In the patients tested thus far, we are observing CTL activity against HIV only in patients treated with REMUNE and not in the patients treated with antiviral drugs alone. These data lend support to the investigational use of REMUNE in conjunction with antiviral drugs in order to rebuild the immune system against HIV. Specifically, boosting the population of CTLs that can kill other cells infected with HIV may enable REMUNE to have a positive impact on viral load,`` said Dr. Fernandez-Cruz.

In addition, Dr. Fernandez-Cruz presented evidence that the REMUNE-induced CTLs were capable of attacking the Clade B strain of HIV. Whereas, REMUNE itself is derived from Clade A/G, an African strain of HIV, the CTLs induced by immunization with REMUNE were able to recognize and attack Clade B, the most common HIV strain in the U.S. and Europe. The same cross-strain reactive ability has also been observed for REMUNE-induced CD4 helper T cells in proliferation tests against HIV.

``These results indicate that the immune responses induced by REMUNE are directed at conserved regions of the virus, or those less likely to mutate,`` said Dr. Fernandez-Cruz. ``This is an important observation given that HIV`s ability to mutate has been a key obstacle to developing effective therapeutic vaccines against HIV. The apparent ability of REMUNE to stimulate broad cross-reactive immune responses that include CTLs to several different strains of the virus suggests that REMUNE may potentially address the mutation issue and also serve as a potential universal immunogen with utility in different regions of the world where different subtypes of the virus prevail.``

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy that is designed to enable the intravenous injection of genes for delivery to the liver.

NOTE: News releases for The Immune Response Corporation are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1999 and subsequent forms 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE(TM) is a trademark of The Immune Response Corporation.

SOURCE: The Immune Response Corporation

[VonHinten]

Zellen des Mörders T gegen das AIDS-Virus scheinen, von Combination
Treatment mit REMUNE(TM) (Untersuchungs-cHiv-1 Immunogen) und den
Antivirendrogedaten aktiviert zu werden, die bei der 13. internationalen
AIDS-Konferenz berichtet werden CARLSBAD, Calif., Jul 13, 2000 /
PRNewswire über COMTEX / -- die immunes Wartekorporation (Nasdaq:
IMNR), die heute verkündet werden, daß einleitende Zwischenklinische Resultate
von einem fortwährenden Versuch der Phase II in Spanien anzeigen, daß
funktionell aktive cytotoxische t-Lymphozyten (CTL) oder " Mörder" t-Zellen
scheinen, in den HIV-positiveeinzelpersonen angeregt zu werden behandelten mit
dem Untersuchungsprodukt REMUNE(TM) (HIV-1 Immunogen) Company`s im
Verbindung mit Antivirendrogetherapie (KUNST). TCLs sind weiße Blutzellen
des immunen Systems, die zu den Tötungzellen fähig sind, die mit HIV angesteckt
werden. Professor Eduardo Fernandez-Cruz, M.D., Ph.D., Divisionschef der
klinischen Immunitätsforschung am Hochschulallgemeinen Krankenhaus "
Gregorio Maranon " in Madrid und allgemeiner Forscher vom Versuch der Phase
II von REMUNE in Spanien stellte die Daten in einer Munddarstellung bei der 13.
internationalen AIDS-Konferenz in Durban, Südafrika dar. Dr. Fernandez-Cruz
kommentierte, " wir beobachtete eine Zunahme einer spezifischen Teilmenge
t-Zellen, die Zelle-Oberfläche Proteine anzeigen, die von ausführendem TCLs in
den REMUNE-treatedeinzelpersonen charakteristisch sind. Wichtig hat diese
Untersuchung auch gezeigt, daß jene ausführenden TCLs funktionell aktiv sind,
das heißt, haben sie die Fähigkeit zum Beenden der Zellen, die ausdrücken
HIV-Antigene. ", Dr. Fernandez-Cruz zeigte an, daß die CTL-Analyse eine
Gesamtmenge von 23 Patienten umfaßt und die früheren Resultate bestätigt, die
anzeigen, daß REMUNE die Bevölkerung des Speichers TCLs (Zellen, die
ausführende TCLs nach Re-exposure zu einem bestimmten Krankheitserreger
werden kann), bei Patienten gleichzeitig auf Antivirendrogetherapie erhöhen kann.
" bei den Patienten prüfte bis jetzt, beobachten wir CTL-Aktivität gegen HIV nur
bei den Patienten, die mit REMUNE behandelt werden und nicht bei den
Patienten, die mit alleinden Antivirendrogen behandelt werden.

[gimmequote!]

@ von hinten,

also du bist mir lieber als alles andere heut. ersten weil ich noch 2500 mit imnr 16,80 aufm buch hab (und n paar mit 7 hihihi), zweitens weil du´s in deutsche übersetzt hast und dann auch noch wegen deines namens; ICH LIEBE DICH! kannst du kochen?

danke, und verzeih mir den scherz

gimmequote!

[VonHinten]

Hi Gimmequote
Habe leider schon einen Freund.........war auch nur ein Witz
Stehe auf Frauen aber Du bist ja keine.
Bin mal gespannt was die Amis heute Kochen.
In diesem sinne ein DICKER KUß ...Blaublut

[e.broker]

Friday July 14, 7:02 am Eastern Time
Company Press Release
SOURCE: The Immune Response Corporation
Clinical Data on REMUNE(TM) (Investigational HIV-1 Immunogen) Selected as a Late Breaker Presentation at the XIII International AIDS Conference in Durban, South Africa
Preliminary Results Suggest the Investigational Use of HIV Immune-Based Therapy Alone or in Combination With Antiviral Drugs to Treat HIV-Infected Individuals
CARLSBAD, Calif., July 14 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that Trinity Medical Group, the Company`s licensee for development of REMUNE in Southeast Asia, has informed the Company that follow-up data from the Phase II clinical trial conducted in Thailand were presented at the XIII International AIDS Conference in Durban, South Africa.

In a late-breaker oral presentation, Vina Churdboonchart, Ph.D., of Mahidol University, Bangkok, Thailand, reported an update on preliminary results from a follow-up study of HIV-infected people who were previously enrolled in a 40-week Phase II trial of Remune in Thailand for which she was the Principal Investigator. The main objective of the Phase II trial was to determine the effect of Remune as a monotherapy on CD4 helper T cells, which are the primary targets of HIV. Patients treated with Remune had significantly higher CD4 counts (an average increase of 84 CD4 cells) compared to the placebo group at the end of the 40-week placebo controlled trial. Furthermore, the increase in CD4 cells was associated with increased immune activity against the virus, as measured by delayed type hypersensitivity skin tests (a measure of cell mediated immunity against HIV) and western blot (a measure of antibodies against HIV).

Upon conclusion and unblinding of the Phase II trial, all patients were allowed to participate in an on-going open-label extension study with continued Remune treatments every 12 weeks without concomitant antiviral drug therapy. Patients are being monitored for changes in immune responses, including number of CD4 helper T cells (specialized white blood cells), in addition to body weight (an indicator of general health) and viral load (the amount of replicating HIV in the bloodstream).

A total of 27 HIV-infected patients participating in the open-label study have completed an additional 96 weeks (total of 136 weeks) of receiving Remune as a monotherapy. Results were reported as a comparison of measurements taken at baseline (at the conclusion of the original 40-week trial) and at 136 weeks. For the entire group, on average, CD4 counts increased by 100 cells, body weight increased by 1.05 kilograms, and viral load remained stable (4,800 copies HIV RNA per mL at baseline vs. 4,700 copies HIV RNA per mL at 136 weeks).

``At the end of the 40-week trial, patients treated with Remune experienced a significant increase in CD4 cells compared to the placebo group. In the subset of patients reaching 136 weeks, we are seeing an even greater increase in CD4 cells with specific activity against HIV, which suggests that improved immune responses may be the result of prolonged treatment with Remune,`` said Dr. Churdboonchart. ``Equally notable is that even without antiviral drug therapy, viral load has remained stable on average for nearly three years in this subset of patients.`` Dr. Churdboonchart added that the patients selected for the Phase II trial were asymptomatic and relatively healthy individuals, such that the observed positive immune responses to treatment with Remune underscore the importance of early intervention to management of HIV infection.

``These data are particularly relevant for this year`s AIDS meeting in Africa as they suggest one potential strategy for slowing the AIDS epidemic in developing countries where access to antivirals is limited,`` Dr. Churdboonchart continued. ``These results support our proposal to Thai health authorities that Remune should be used as a first line therapy, with cost-effective antivirals added on for non-responding patients. The stability of these patients receiving REMUNE alone is comparable to that of clinical non-progressors. These new data will be submitted to the Thai Ministry of Public Health (the Thai FDA).``

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy that is designed to enable the intravenous injection of genes for delivery to the liver.

NOTE: News releases for The Immune Response Corporation are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether Remune will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1999 and subsequent forms 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Remune (TM) is a trademark of The Immune Response Corporation.

SOURCE: The Immune Response Corporation